These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36794497)

  • 21. Fluoroquinolones for treating tuberculosis.
    Ziganshina LE; Squire SB
    Cochrane Database Syst Rev; 2008 Jan; (1):CD004795. PubMed ID: 18254061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin.
    Firsov AA; Zinner SH; Vostrov SN; Portnoy YA; Lubenko IY
    J Antimicrob Chemother; 2002 Oct; 50(4):533-9. PubMed ID: 12356798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
    Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
    Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disproportionality analysis of spontaneously reported hypoglycemia events due to insulin use: A comparison between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System.
    Jeong D; Kim W; Shin JY
    Int J Clin Pharmacol Ther; 2021 Mar; 59(3):224-230. PubMed ID: 33191903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-approval Safety Monitoring of Quadrivalent and Bivalent Human Papillomavirus Vaccines Based on Real-world Data from the Korea Adverse Events Reporting System (KAERS).
    Kim M; Kim S; Shin JY
    Clin Drug Investig; 2020 Aug; 40(8):727-735. PubMed ID: 32474825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use.
    Sachs B; Riegel S; Seebeck J; Beier R; Schichler D; Barger A; Merk HF; Erdmann S
    Drug Saf; 2006; 29(11):1087-100. PubMed ID: 17061914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions.
    Jones SC; Budnitz DS; Sorbello A; Mehta H
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1099-106. PubMed ID: 23963962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.
    Lubasch A; Keller I; Borner K; Koeppe P; Lode H
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2600-3. PubMed ID: 10991830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
    Evans ME
    Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
    Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
    Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating the performance of machine learning methods and variable selection methods for predicting difficult-to-measure traits in Holstein dairy cattle using milk infrared spectral data.
    Mota LFM; Pegolo S; Baba T; Peñagaricano F; Morota G; Bittante G; Cecchinato A
    J Dairy Sci; 2021 Jul; 104(7):8107-8121. PubMed ID: 33865589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
    Frothingham R
    Pharmacotherapy; 2001 Dec; 21(12):1468-72. PubMed ID: 11765299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.
    Jones SC; Sorbello A; Boucher RM
    Drug Saf; 2011 Oct; 34(10):839-47. PubMed ID: 21879778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of machine learning approaches for osteoporosis risk prediction in postmenopausal women.
    Shim JG; Kim DW; Ryu KH; Cho EA; Ahn JH; Kim JI; Lee SH
    Arch Osteoporos; 2020 Oct; 15(1):169. PubMed ID: 33097976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility.
    García-Olmos M; Parra A; García-Calvo G; Ponte C; Giménez MJ; Aguilar L; Soriano F
    Int J Antimicrob Agents; 2003 Jun; 21(6):568-73. PubMed ID: 12791471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison.
    Duggirala A; Joseph J; Sharma S; Nutheti R; Garg P; Das T
    Indian J Ophthalmol; 2007; 55(1):15-9. PubMed ID: 17189881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of three fluoroquinolones on QT interval in healthy adults after single doses.
    Noel GJ; Natarajan J; Chien S; Hunt TL; Goodman DB; Abels R
    Clin Pharmacol Ther; 2003 Apr; 73(4):292-303. PubMed ID: 12709719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluoroquinolones for treating tuberculosis.
    Ziganshina LE; Vizel AA; Squire SB
    Cochrane Database Syst Rev; 2005 Jul; (3):CD004795. PubMed ID: 16034951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.